|

Crizotinib 250 MG Clinical Trials

2 actively recruiting trials

Also known as: Entrectinib, Xalkori

Pipeline

Phase 2: 2

Top Sponsors

  • Hunan Province Tumor Hospital1
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences1

Indications

  • Cancer2
  • MET Gene Mutation1
  • ROS1 Gene Mutation1
  • Rare Tumor1
  • ALK Gene Mutation1

Other2 trials

PLATFORM Study of Precision Medicine for Rare Tumors
Phase 2
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.